Literature DB >> 12586291

Incidence and natural history of small esophageal varices in cirrhotic patients.

Manuela Merli1, Giorgia Nicolini, Stefania Angeloni, Vittorio Rinaldi, Adriano De Santis, Carlo Merkel, Adolfo Francesco Attili, Oliviero Riggio.   

Abstract

BACKGROUND/AIMS: The incidence and natural history of small esophageal varices (EV) in cirrhotics may influence the frequency of endoscopies and the decision to start a pharmacological treatment in these patients.
METHODS: We prospectively evaluated 206 cirrhotics, 113 without varices and 93 with small EV, during a mean follow-up of 37+/-22 months. Patients with previous gastrointestinal bleeding or receiving any treatment for portal hypertension were excluded. Endoscopy was performed every 12 months.
RESULTS: The rate of incidence of EV was 5% (95%CI: 0.8-8.2%) at 1 year and 28% (21.0-35.0%) at 3 years. The rate of EV progression was 12% (5.6-18.4%) at 1 year and 31% (21.2-40.8%) at 3 years. Post-alcoholic origin of cirrhosis, Child-Pugh's class (B or C) and the finding of red wale marks at first examination were predictors for the variceal progression. The two-years risk of bleeding from EV was higher in patients with small varices upon enrollment than in those without varices: 12% (95% CI: 5.2-18.8%) vs. 2% (0.1-4.1%); (P<0.01). Predictor for bleeding was the presence of red wale marks at first endoscopy.
CONCLUSIONS: In patients with no or small EV, endoscopy surveillance should be planned taking into account cause and degree of liver dysfunction.

Entities:  

Mesh:

Year:  2003        PMID: 12586291     DOI: 10.1016/s0168-8278(02)00420-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  116 in total

Review 1.  Performance of platelet count/spleen diameter ratio for diagnosis of esophageal varices in cirrhosis: a meta-analysis.

Authors:  Li Ying; Xiao Lin; Zuo-Liu Xie; Yuan-Ping Hu; Ke-Qing Shi
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

Review 2.  [Classification and management of upper gastrointestinal bleeding].

Authors:  K Herrlinger
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

3.  Hepatobiliary quiz-5 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-03

Review 4.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

5.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 6.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

Review 7.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part 1.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2007-11-09       Impact factor: 3.199

Review 8.  Quality improvement in gastroenterology clinical practice.

Authors:  Rakhi Kheraj; Sumeet K Tewani; Gyanprakash Ketwaroo; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

9.  Proton pump inhibitor administration delays rebleeding after endoscopic gastric variceal obturation.

Authors:  Won Seok Jang; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Jae Myung Cha; Jung Won Jeon; Jun Uk Lim
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Does gastroesophageal reflux have an influence on bleeding from esophageal varices?

Authors:  Eisuke Okamoto; Yuji Amano; Hiroyuki Fukuhara; Koichiro Furuta; Tatsuya Miyake; Shuichi Sato; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.